Bill > AJR181

This Joint Resolution establishes the New Jersey Pharmacogenomics Commission, a body tasked with studying pharmacogenomics, which is the science of how an individual's genetic makeup influences their response to medications, including their effectiveness and potential side effects. The commission will investigate various aspects of pharmacogenomics, such as its costs, benefits to patients and healthcare providers, applications beyond medicine, its role in personalized medicine, and its potential to reduce adverse drug events, which are harmful reactions to medications. The commission will be composed of thirteen members appointed by various state officials and legislative leaders, representing diverse fields including healthcare, pharmacy, and genetics, and will serve without compensation but be reimbursed for expenses. It is required to hold public hearings and will submit a report of its findings and recommendations to the Governor and Legislature before its dissolution.